People's Liberty to spark change in OTR

CINCINNATI People's Liberty is open for business.

The philanthropic laboratory unveiled its newly renovated office space Friday in the old Globe furniture building near Findlay Market in Over-the-Rhine.

"This is a big day in the life of People's Liberty," said CEO Eric Avner. "This is the real concrete beginning of our activities."

For People's Liberty, those activities all revolve around investing in people to show that philanthropy focused on individuals can change communities.

The organization announced its first two Haile Fellows late last year, awarding each a $100,000 cash prize and 12 months of working space in the Globe building. Its first gallery installment at the building will open Friday evening. And in the coming months it will be awarding project grants of up to $10,000 each, too.

Eric Avner, CEO of Peoples Liberty, led a tour through the building on March 27, 2015. Emily Maxwell | WCPO

The building renovation has allowed People's Liberty to invest in other important ways, too, Avner said. The Carol Ann and Ralph V. Haile, Jr./U.S. Bank Foundation one of the People's Liberty funders has spent about $3.6 million on the renovation. And the vast majority of the work on the project has gone to businesses located in or near Over-the-Rhine, Avner said.

Camp Washington-based Brush Factory was among them.

Owned by Rosie Kovacs and Hayes Shanesy, who live in Over-the-Rhine, Brush Factory designs and makes furniture for homes, offices, restaurants and retail spaces.

See the article here:

People's Liberty to spark change in OTR

WILD ONES – "Show Me Islands" (Live in Austin, TX 2015) #JAMINTHEVAN – Video


WILD ONES - "Show Me Islands" (Live in Austin, TX 2015) #JAMINTHEVAN
Wild Ones - "Show Me Islands" Live at the GQ Artist House in Austin, TX with Jam in the Van. Subscribe to Jam in the Van! http://bit.ly/subthejamvan GET THE AUDIO HERE: http://www.jaminthevan.c...

By: Jam In The Van

Here is the original post:

WILD ONES - "Show Me Islands" (Live in Austin, TX 2015) #JAMINTHEVAN - Video

SAINT KITTS & NEVIS 6-2 TURKS & CAICOS ISLANDS 2018 FIFA World Cup Qualifiers – Goals – Video


SAINT KITTS NEVIS 6-2 TURKS CAICOS ISLANDS 2018 FIFA World Cup Qualifiers - Goals
The two first goals are unfortunately missing. Second version with one less goal: http://youtu.be/9lufhRgLbHY First version with two less goals: http://youtu.be/6hR2-qHiBUU.

By: Krokomime

Go here to see the original:

SAINT KITTS & NEVIS 6-2 TURKS & CAICOS ISLANDS 2018 FIFA World Cup Qualifiers - Goals - Video

What if the severity of our seasonal influenza were related to our genetic background?

While most of us recover from influenza after a week, it can be a very severe disease, and even fatal in rare cases, with no reason for physicians to have expected such an outcome. By analysing the genome of a little girl who contracted a severe form of influenza at the age of two and a half years, researchers at the Laboratory of Human Genetics of Infectious Diseases (a joint French-American international laboratory), which brings together researchers from Inserm, Paris Descartes University, and physicians from the Paris public hospitals (AP-HP; Necker Hospital for Sick Children), working at the Imagine Institute, and from The Rockefeller University in New York, have discovered that she has a genetic mutation, unknown until now, that causes a subtle dysfunction in her immune system. More generally, these results show that genetic mutations could be the root cause of some severe forms of influenza in children, and indicate in any event that immune mechanisms missing in this little girl are needed for protection against this virus in humans. These results are published in the journal Science.

Seasonal influenza is an acute viral infection caused by the influenza virus. It is characterised by high fever, headaches, sore muscles, etc. Apart from vaccination, there is no treatment for it other than symptomatic (pain) treatment. In most cases, patients recover after a week, but in more vulnerable people influenza can cause acute respiratory distress, which is potentially fatal.

The main known risk factors for severe forms of influenza are some acquired comorbidities, such as chronic lung disease. However, the cause of most fatal cases remains unexplained, especially in children.

The absence of cases of severe influenza in patients with known acquired immunodeficiencies, which usually increase susceptibility to infections, is also surprising.

Given these different observations, the researchers at Jean-Laurent Cassanova's and Laurent Abel's laboratory, in Paris and New York, therefore formulated a hypothesis whereby severe influenza in healthy children might be the result of genetic errors.

To test this hypothesis, they sequenced the entire genome of a 7-year-old child who had contracted a severe form of influenza (influenza A virus strain H1N1), requiring her admission to a paediatric intensive care unit in January 2011, at the age of two and a half years. At the time, she showed no other known pathology that might have suggested greater vulnerability to the virus than that of other children.

This analysis, combined with analysis of her parents' genomes, made it possible to show that the little girl had inherited a mutated allele of the gene encoding interferon regulatory factor (IRF7) from both of her parents. The latter is a transcription factor known to amplify the production of interferons in response to viral infection in mice and humans.

In contrast to her parents, in whom the mutation of a single allele of the gene is of no consequence, in the little girl, mutation of both alleles of the gene encoding IRF7 has led to its inactivation. The result: failure to produce interferons, disrupting her system of defence against influenza virus infection in a cascading manner.

By carrying out a comprehensive series of experiments on blood cells, particularly dendritic cells, and by generating lung cells from stem cells taken from the young girl, the researchers provided proof that the mutations observed in this little girl explain the development of severe influenza. Furthermore, this discovery demonstrates that interferon amplification dependent on IRF7 expression is needed for protection against influenza virus in humans. They now need to search for mutations in this or other genes in other children recruited following an episode of unexplained severe influenza.

Based on these initial observations, the researchers at Inserm believe that therapeutic strategies based on recombinant interferons, available in the pharmacopoeia, could help to combat severe forms of influenza in children.

See original here:

What if the severity of our seasonal influenza were related to our genetic background?

Roxane Vezina Canadian Hippocrates Health Institute Guest (French) – Video


Roxane Vezina Canadian Hippocrates Health Institute Guest (French)
Located on a lush 50 acre campus in West Palm Beach, Florida, Hippocrates Health Institute is the leader in the field of natural and alternative health care. For over 60 years, we have dedicated...

By: Hippocrates Health Institute

Link:

Roxane Vezina Canadian Hippocrates Health Institute Guest (French) - Video

Health Care REIT Series J Cumulative Redeemable Preferred Stock Ex-Dividend Reminder

On 3/31/15, Health Care REIT Inc.'s 6.50% Series J Cumulative Redeemable Preferred Stock (Symbol: HCN.PRJ) will trade ex-dividend, for its quarterly dividend of $0.4062, payable on 4/15/15. As a percentage of HCN.PRJ's recent share price of $27.02, this dividend works out to approximately 1.50%, so look for shares of HCN.PRJ to trade 1.50% lower - all else being equal - when HCN.PRJ shares open for trading on 3/31/15. On an annualized basis, the current yield is approximately 6.06%, which compares to an average yield of 6.96% in the "Real Estate" preferred stock category, according to Preferred Stock Channel . The chart below shows the one year performance of HCN.PRJ shares, versus HCN:

Click here to learn which S.A.F.E. dividend stocks also have preferred shares that should be on your radar screen

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.

View original post here:

Health Care REIT Series J Cumulative Redeemable Preferred Stock Ex-Dividend Reminder

Health Care Sector Update for 03/27/2015: CNAT,BMRN,OHRP

Top Health Care Stocks

JNJ +0.45%

PZE +0.97%

MRK +0.82%

ABT +0.55%

AMGN +1.38%

Health care stocks were broadly higher today with the NYSE Health Care Sector Index jumping almost 0.8% and shares of health care companies in the S&P 500 rising 0.9% as a group.

In company news, Conatus Pharmaceuticals ( CNAT ) extended gains Friday after the biotech company said Thursday that its emricasan drug candidate met its primary goal of reducing three biomarkers signaling liver damage during Phase II testing in patients with nonalcoholic fatty liver disease.

The double-blind, placebo-controlled trial enrolled 38 patients receiving either 25 milligrams of emricasan or a placebo twice daily. According to the company, 30% of the patients in emricasan arm demonstrated declines in the three enzymes compared with just a 4% drop in the placebo arm.

The drug also was safe and well tolerated during the latest trial, with no dose-limiting toxicities and no drug-related serious adverse events observed. CNAT plans to present detailed trial results at the International Liver Congress beginning April 22 in Vienna, Austria.

Read more:

Health Care Sector Update for 03/27/2015: CNAT,BMRN,OHRP

In A Genetic Portrait Of A Nation, A Map Of The Future

Its the most complete genetic map of an entire country yet completed and it could show clues of what medicine could look like in the coming age of big data.

Researchers working at DeCode Genetics, a unit of the drug company Amgen, have sequenced the genomes of 2,636 Icelanders and used genealogical records and more spotty genetic data to calculate the likely genetics of 101,584 more. Because DeCode has anonymized access to patient medical records, the company could then look for relationships between the genetic variants and disease and they found a new genetic variant that increases the risk of Alzheimers, as well as confiming suspected variants that raise the risk of diabetes and one that causes atrial fibrillation, a heart condition. The results are published in three scientific papers in the journal Nature.

Its certainly an impressive tour de force, says George Yancopoulos, the Chief Scientific Officer of Amgen rival Regeneron. This is certainly establishing a benchmark for all of us and showing the value of this type of analysis, in particular in the Icelandic population.

Regeneron is creating its own database of sequencing data with Pennsylvanias Geisinger Health Systems. The United Kingdom has embarked on a 100,000 Genomes Project. And President Obama has proposed linking together lots of ongoing sequencing projects into a database of 1 million volunteers. The DeCode experiment, started 18 years ago during the dot-com boom, is our first look at the kind of data that these gargantuan efforts could produce.

Some important basic science questions were answered. For instance, a lot of effort is put into figuring out when the most recent common male ancestor of all people has lived, an area of research that could be important for understanding of diseases linked to the (male) Y chromosome. But Amgen bought DeCode, and its access to Icelands population for $415 million two years ago. It didnt spend that kind of coin to find out about the mutation rate on the Y chromosome.

The hope has always been that these kinds of genetic data would lead to new drugs. And DeCode provides a series of huge leads. Scientists frequently try to figure out what genes do by knocking them out (that is, breaking them) in mice. Doing the same experiment in humans would be, of course, highly unethical.

Except that some people are born with naturally dysfunctional copies of some genes. And these can be clues to drugs. Theres even a great example: having a dysfunctional version of a gene called PCSK9 results in lower cholesterol levels and rates of heart disease. There are even people with two broken copies of the gene, including an aerobics instructor in Dallas who has levels of LDL, or bad cholesterol, of 14 milligrams per deciliter, compared to normal levels of more than 100 mg/dL.

Both Amgen and Regeneron have drugs (evolocumab and alirocumab) that block PCSK9 that will soon hit the market, in what is expected to be one of the most heated drug launches in years. Drug company executives hope that more genetic data would mean finding more genes like PCSK9 that could be useful drug targets.

Read the original here:

In A Genetic Portrait Of A Nation, A Map Of The Future